Emily Freilich, MD, is the Director of the Division of Neurology 1 within the Office of New Drugs in FDA’s Center for Drug Evaluation and Research. Dr. Freilich is a board-certified pediatric neurologist.  Dr. Freilich graduated from Duke University with a Bachelor of Science degree in biology and received her medical degree from Rutgers-New Jersey Medical School. She completed her pediatric residency and child neurology training at Children’s National Health System in Washington, D.C. Prior to joining FDA, Dr. Freilich worked at Children’s National and the Pediatric Specialists of Virginia, where she was a general child neurologist with special interest in rare pediatric epilepsies, served as co-director of the Tuberous Sclerosis Clinic, and was an Assistant Professor of Pediatrics and Neurology at George Washington University School of Medicine.  She joined the Division of Neurology Products at FDA in 2016 as a clinical reviewer working in the areas of epilepsy and migraine and subsequently transitioned to a team leader in the Division of Neurology 1 for review of treatments for neuromuscular and rare neurologic disorders. She subsequently served as Acting Associate Director for Therapeutic Review and Acting Deputy Director in the Division of Neurology 1 prior to her current role.